MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors

Starting soon · Early Phase 1

Conditions studied: Healthy Volunteers, Recurrent Glioma, Brain Metastases From Extra-cranial Solid Tumors

In brief

This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET) imaging of primary and metastatic brain tumors. This study will include 3 cohorts: healthy volunteers for whole body dosimetry estimates (n=6-8, Dosimetry Cohort), patients undergoing evaluation for recurrent high grade glioma after radiation therapy (n=10, high grade glioma (HGG) Cohort), and patients with brain metastases from extra-cranial solid tumors before and after radiation therapy (n=10, Metastasis Cohort). Exploratory assessment of the diagnostic accuracy of MeFAMP for distinguishing recurrent/progressive brain tumors from radiation-related treatment effects will also be performed for subsequent trial design. The study will complete accrual and safety assessment in the Dosimetry Cohort before recruiting for the HGG and Metastasis Cohorts.

Key facts

Study ID
NCT05676489
Run by
University of Alabama at Birmingham
People needed
28
Starts
2027-04-01
Expected to finish
2029-08-30
Last updated by the study team
2026-06-02

Who can join

Age: 2 and older, up to 89. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.